US Stock MarketDetailed Quotes
NBY NovaBay Pharmaceuticals
- 0.1318
- -0.0082-5.86%
Close May 24 16:00 ET
- 0.1327
- +0.0009+0.68%
Post 19:45 ET
4.99MMarket Cap-40P/E (TTM)
0.1474High0.1311Low9.77MVolume0.1422Open0.1400Pre Close1.35MTurnover25.94%Turnover RatioLossP/E (Static)37.83MShares1.280052wk High-3.77P/B4.96MFloat Cap0.065052wk Low--Dividend TTM37.66MShs Float3718.7485Historical High--Div YieldTTM11.64%Amplitude0.0650Historical Low0.1380Avg Price1Lot Size
NovaBay Pharmaceuticals Key Stats
Quarterly+Annual
YOY
| (Q1)Mar 31, 2024 | (FY)Dec 31, 2023 | (Q4)Dec 31, 2023 | (Q3)Sep 30, 2023 | (Q2)Jun 30, 2023 | (Q1)Mar 31, 2023 | (FY)Dec 31, 2022 | (Q4)Dec 31, 2022 | (Q3)Sep 30, 2022 | (Q2)Jun 30, 2022 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Total revenue | 12.48%2.63M | 2.24%14.73M | 2.31%3.73M | -14.66%3.27M | 25.89%4.61M | -28.54%2.34M | 41.16%14.4M | 14.81%3.64M | 68.92%3.83M | 71.68%3.66M |
| Operating revenue | 12.52%2.62M | 2.18%14.69M | 2.34%3.72M | -14.70%3.26M | 25.66%4.6M | -28.62%2.33M | 41.20%14.37M | 14.61%3.63M | 68.92%3.82M | 72.15%3.66M |
| Cost of revenue | 13.26%837K | 3.14%6.83M | 1.27%1.91M | -1.65%1.43M | 26.32%2.3M | -49.35%739K | 79.53%6.62M | 26.29%1.89M | 103.79%1.45M | 197.07%1.82M |
| Gross profit | 12.13%1.79M | 1.47%7.9M | 3.42%1.82M | -22.61%1.84M | 25.46%2.31M | -11.80%1.6M | 19.43%7.78M | 4.59%1.76M | 52.93%2.38M | 21.00%1.84M |
| Operating expense | 14.26%3.37M | -16.58%12.9M | -41.20%2.61M | 4.31%2.95M | -8.25%3.66M | -29.81%2.95M | 0.55%15.46M | -8.78%4.44M | -26.29%2.83M | 18.12%3.99M |
| Selling and administrative expenses | 14.00%3.35M | -16.07%12.83M | -40.41%2.61M | 5.45%2.94M | -8.00%3.63M | -29.58%2.94M | -0.30%15.29M | -9.99%4.38M | -27.17%2.79M | 17.66%3.95M |
| -Selling and marketing expense | -14.64%1.06M | -16.65%6.5M | -27.04%1.41M | -6.54%1.72M | -15.78%1.72M | -37.35%1.24M | -3.65%7.8M | -9.90%1.94M | -10.97%1.84M | 14.09%2.04M |
| -General and administrative expense | 34.84%2.29M | -15.48%6.33M | -51.02%1.2M | 28.45%1.23M | 0.31%1.92M | -22.60%1.7M | 3.44%7.49M | -10.06%2.44M | -46.02%956K | 21.73%1.91M |
| Research and development costs | 90.00%19K | -60.92%68K | -93.94%4K | -73.17%11K | -32.50%27K | -64.29%10K | 295.45%174K | 725.00%66K | 310.00%41K | 90.48%40K |
| Operating profit | -16.80%-1.57M | 34.86%-5M | 70.32%-798K | -144.20%-1.12M | 37.04%-1.36M | 43.53%-1.35M | 13.34%-7.68M | 15.81%-2.69M | 80.03%-457K | -15.76%-2.15M |
| Net non-operating interest income expense | -433K | 0 | ||||||||
| Non-operating interest expense | --433K | ---- | ---- | ---- | ---- | --0 | ---- | ---- | ---- | ---- |
| Other net income (expense) | -1.09M | -58.37%-4.64M | 40.00%-3.31M | -299.69%-641K | -22,600.00%-681K | -196.38%-2.93M | -281.72%-5.52M | 321K | -3K | |
| Gain on sale of security | --259K | -99.43%20K | -94.98%49K | ---- | --256K | ---- | -23.64%3.52M | --976K | --492K | ---- |
| Special income (charges) | ---865K | 58.01%-2.59M | 59.45%-2.59M | --0 | ---- | --0 | ---6.18M | ---6.4M | --0 | ---- |
| -Less：Restructuring and merger&acquisition | ---- | --0 | --0 | --0 | ---- | ---- | ---561K | ---342K | --0 | ---- |
| -Less:Impairment of capital assets | ---- | -61.51%2.59M | ---- | ---- | ---- | ---- | --6.74M | ---- | ---- | ---- |
| -Gain on sale of business | ---865K | ---- | ---- | ---- | ---- | --0 | ---- | ---- | ---- | ---- |
| Other non- operating income (expenses) | ---480K | -647.83%-2.06M | -681.63%-766K | -274.85%-641K | -31,133.33%-937K | ---- | 82.50%-276K | 93.79%-98K | ---171K | ---3K |
| Income before tax | -129.74%-3.09M | 9.13%-9.64M | 49.94%-4.11M | -1,191.91%-1.76M | 5.52%-2.04M | -1,111.71%-1.35M | -82.14%-10.61M | -5,093.67%-8.21M | 94.06%-136K | -15.92%-2.16M |
| Income tax | ||||||||||
| Net income | -84.82%-3.21M | 9.13%-9.64M | 49.94%-4.11M | -1,191.91%-1.76M | 5.52%-2.04M | -1,466.67%-1.74M | -82.14%-10.61M | -5,093.67%-8.21M | 94.06%-136K | -15.92%-2.16M |
| Net income continuous Operations | -129.74%-3.09M | 9.13%-9.64M | 49.94%-4.11M | -1,191.91%-1.76M | 5.52%-2.04M | -1,111.71%-1.35M | -82.14%-10.61M | -5,093.67%-8.21M | 94.06%-136K | -15.92%-2.16M |
| Net income discontinuous operations | 68.53%-124K | ---- | ---- | ---- | ---- | ---394K | ---- | ---- | ---- | ---- |
| Minority interest income | ||||||||||
| Net income attributable to the parent company | -84.82%-3.21M | 9.13%-9.64M | 49.94%-4.11M | -1,191.91%-1.76M | 5.52%-2.04M | -1,466.67%-1.74M | -82.14%-10.61M | -5,093.67%-8.21M | 94.06%-136K | -15.92%-2.16M |
| Preferred stock dividends | ||||||||||
| Other preferred stock dividends | 380K | 24.75%7.06M | 5.06M | 0 | 2M | 0 | 5.66M | 0 | 5.66M | 0 |
| Net income attributable to common stockholders | -106.67%-3.59M | -2.66%-16.7M | -11.74%-9.17M | 69.67%-1.76M | -87.10%-4.03M | -1,466.67%-1.74M | -147.98%-16.27M | -818.92%-8.21M | -153.08%-5.79M | -15.92%-2.16M |
| Basic earnings per share | 82.35%-0.15 | 60.79%-3.96 | 82.92%-0.8165 | 89.75%-0.37 | 11.19%-1.27 | -962.50%-0.85 | -92.02%-10.1 | -573.24%-4.78 | -106.29%-3.61 | -2.14%-1.43 |
| Diluted earnings per share | 82.35%-0.15 | 60.79%-3.96 | 82.92%-0.8165 | 89.75%-0.37 | 11.19%-1.27 | -962.50%-0.85 | -92.02%-10.1 | -573.24%-4.78 | -106.29%-3.61 | -2.14%-1.43 |
| Dividend per share | ||||||||||
| Currency Unit | USD | USD | USD | USD | USD | USD | USD | USD | USD | USD |
| Accounting Standards | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP |
| Audit Opinions | -- | -- | -- | -- | -- | -- | Unqualified Opinion with Explanatory Notes | -- | -- | -- |
Analysis
Price Target
No Data
Heat List
US
Overall
Symbol
Latest Price
%Chg